Know Cancer

or
forgot password

A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129


Phase 2
18 Years
N/A
Not Enrolling
Both
Non-Small Cell Lung Cancer

Thank you

Trial Information

A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129


OUTLINE: This is a multi-center study.

- Pemetrexed (Alimta) 500mg/m2 administered intravenously over approximately 10-minutes
on Day 1 of a 21-day cycle x 3 cycles

- Radiation will start between days -1 to 2 from day 1 of cycle 1. Day 1 radiotherapy
must be a Monday, Tuesday, or Wednesday.

The planned radiation dose is 60 Gy in 2.0 Gy fractions. The entire PTV, including primary
tumor and areas of known nodal disease, shall receive 60 Gy at 2.0 Gy fractions, 5
fractions/week for 30 fractions over 6 weeks.

Performance Status: ECOG performance status 2

Life Expectancy: Not specified

Hematopoietic:

- Platelets ≥ 100 K/mm3

- Absolute Neutrophil Count (ANC) ≥ 2.0 K/mm3

Hepatic:

- Aspartate transaminase (AST) ≤ 2.5 x ULN.

- Alanine transaminase (ALT) ≤ 2.5 x ULN.

- Total bilirubin ≤ 1.5 x ULN

Renal:

- Calculated creatinine clearance (using Cockcroft-Gault formula) ≥ 45 cc/min

Cardiovascular:

- No significant history of cardiac disease. Must not have unstable angina (anginal
symptoms at rest).

Pulmonary:

- Forced expiratory volume in 1 second (FEV1) greater than 1L


Inclusion Criteria:



- Histological or cytological proof of Non Small Cell Lung Cancer (NSCLC)

- Measurable or non-measurable disease per RECIST as evaluated by imaging within 28
days prior to registration for protocol therapy

- Unresectable Stage IIIA or IIIB disease as evaluated by imaging within 28 days prior
to registration for protocol therapy

- Weight loss of greater than 10% in the preceding six months prior to registration for
protocol therapy.

- Serum albumin < 0.85 x institutional lower limit of normal

- Able and willing to interrupt non-steroidal anti-inflammatory agents for 2 days
before (5 days for long acting agents such as piroxicam), the day of, and 2 days
following administration of pemetrexed

- Lung V20 < 35% within 14 days prior to registration for protocol therapy, as planned
by the radiation oncologist

- Mean lung dose < 20 Gy within 14 days prior to registration for protocol therapy, as
planned by the radiation oncologist

- Written informed consent and HIPAA authorization for release of personal health
information

- Age ≥ 18 years

- Females of childbearing potential and males must be willing to use an effective
method of contraception (hormonal or barrier method of birth control; abstinence)
from the time of consent until at least 90 days following completion of study
treatment.

- Females of childbearing potential must have a negative pregnancy test within 7 days
prior to registration for protocol therapy. Patients are considered not of child
bearing potential if they are surgically sterile (they have undergone a hysterectomy,
bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal.

Exclusion Criteria:

- Patients with malignant pleural effusions are not eligible. The only exception is a
patient with a pleural effusion visible only on CT scan (and not visible on CXR) OR
deemed too small to tap.• No CNS metastases. All patients must undergo a CT scan/MRI
of the brain within 28 days prior to registration for protocol therapy to exclude
brain metastasis.

- No prior chemotherapy, adjuvant therapy or radiotherapy for lung cancer.

- No metastatic disease as determined by PET scan within 28 days prior to registration
for protocol therapy.

- No active clinically serious infections as judged by the treating investigator (> CTC
v3, Grade 2) including known human immunodeficiency virus (HIV) infection or chronic
Hepatitis B or C.

- No other active malignancies.

- No history of collagen vascular disease (CVD).

- No significant history of cardiac disease. Must not have unstable angina (anginal
symptoms at rest).

- No history of psychiatric illness/social situations that would limit compliance with
study requirements.

- Females must not be breastfeeding.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

- To determine progression free survival in patients with poor risk stage III NSCLC treated with pemetrexed and concurrent definitive radiation

Outcome Time Frame:

24 months

Safety Issue:

No

Principal Investigator

Nasser Hanna, M.D.

Investigator Role:

Study Chair

Investigator Affiliation:

Hoosier Oncology Group

Authority:

United States: Institutional Review Board

Study ID:

LUN08-129

NCT ID:

NCT00732303

Start Date:

August 2008

Completion Date:

December 2010

Related Keywords:

  • Non-Small Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location

Siteman Cancer CenterSaint Louis, Missouri  63110
Providence Portland Medical CenterPortland, Oregon  97213-3635
Northwestern University Feinberg School of MedicineChicago, Illinois  60611
Northern Indiana Cancer Research ConsortiumSouth Bend, Indiana  
Medical & Surgical Specialists, LLCGalesburg, Illinois  61401
Cancer Care Center Of Southern IndianaBloomington, Indiana  47403
Horizon Oncology CenterLafayette, Indiana  47905
Providence Medical GroupTerre Haute, Indiana  47802
Community Regional Cancer CenterIndianapolis, Indiana  46256
Medical Consultants, P.C.Muncie, Indiana  47303
Fort Wayne Oncology & Hematology, IncFort Wayne, Indiana  46815
Hematology Oncology Associates S.J., P.A.Mt. Holly, New Jersey  08060
Pennsylvania Oncology-Hematology AssociatesPhiladelphia, Pennsylvania  19106
Fox Chase Cancer Center Extramural Research ProgramRockledge, Pennsylvania  19046
Indiana University Simon Cancer CenterIndianapolis, Indiana  46202
IN Onc/Hem AssociatesIndianapolis, Indiana  46202
Monroe Medical AssociatesMunster, Indiana  46321
NorthShore University Health System - Kellogg Cancer CenterEvanston, Illinois  60201